Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | ELOC | Q15369 | 1/20 | 0.37 |
| ▸ | ELOB | Q15370 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327268 | 0.79 | MGLL (0.55) | AOC2MAPTVHLELOCELOB | |
| SCHEMBL8056210 | 0.79 | VHL (0.55) | AOC2MAPTVHLELOCELOB | |
| SCHEMBL8539519 | 0.77 | GABRA1 (0.50) | GABRA1GABRB2PNMTTAAR1SLC6A2 | |
| SCHEMBL321086 | 0.76 | AOC2 (0.49) | AOC2MAPTVHLELOCELOB | |
| SCHEMBL4576037 | 0.75 | PRMT6 (0.59) | MAPT | |
| SCHEMBL278321 | 0.75 | LMNA (0.53) | MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL5130756 | 0.75 | AOC2 (0.56) | AOC2MAPTFFAR4 | |
| SCHEMBL20780668 | 0.75 | AOC2 (0.51) | AOC2MAPTVHLELOCELOB | |
| SCHEMBL201853 | 0.75 | AOC2 (0.51) | AOC2MAPTVHLELOCELOB | |
| SCHEMBL1508370 | 0.75 | VHL (0.61) | AOC2MAPTVHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942346-B1 | PYRIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8133898-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100137310-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| WO-2008121506-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137310-A1 | RENIN INHIBITORS | REN, ACE, PRSS3 | AOC2 1938/4885MAPT 3373/4885GABRA1 4000/4885 |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | AOC2 3820/4885MAPT 4724/4885GABRA1 2633/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | AOC2 3916/4885MAPT 4678/4885GABRA1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.